Nuveen LLC Makes New $194,000 Investment in Ventyx Biosciences, Inc. $VTYX

Nuveen LLC bought a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 168,420 shares of the company’s stock, valued at approximately $194,000. Nuveen LLC owned 0.24% of Ventyx Biosciences as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC bought a new stake in Ventyx Biosciences during the first quarter worth approximately $28,000. Bank of America Corp DE boosted its position in Ventyx Biosciences by 376.4% during the fourth quarter. Bank of America Corp DE now owns 4,273,442 shares of the company’s stock worth $9,359,000 after purchasing an additional 3,376,446 shares during the period. BNP Paribas Financial Markets bought a new stake in Ventyx Biosciences during the fourth quarter worth approximately $276,000. Millennium Management LLC boosted its position in Ventyx Biosciences by 369.7% during the fourth quarter. Millennium Management LLC now owns 1,281,629 shares of the company’s stock worth $2,807,000 after purchasing an additional 1,008,760 shares during the period. Finally, Two Sigma Investments LP boosted its position in Ventyx Biosciences by 79.8% during the fourth quarter. Two Sigma Investments LP now owns 476,291 shares of the company’s stock worth $1,043,000 after purchasing an additional 211,421 shares during the period. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Trading Down 3.1%

VTYX opened at $2.52 on Friday. Ventyx Biosciences, Inc. has a 1-year low of $0.78 and a 1-year high of $3.39. The stock has a market capitalization of $179.70 million, a price-to-earnings ratio of -1.50 and a beta of 0.95. The business has a 50 day moving average of $2.65 and a 200-day moving average of $1.93.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.07. Equities analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Ventyx Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.